First-dose safety study of ABL503 for advanced cancers
Part of Cancer clinical trials.
This Phase 1 trial tests the safety and side effects of ABL503 and finds the best dose to study next. It is for people with advanced cancer that is growing despite prior treatment options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced solid tumor that is progressing and cannot be removed or has spread, despite prior treatment (or no standard treatment fits).
- Your recent side effects from previous treatment are mostly back to mild level (with some exceptions like hair loss).
- Your blood counts and organ function (kidneys and liver) are healthy enough on recent lab tests done before starting.
- You have not had certain cancer medicines or therapies very recently (timing depends on the treatment type).
- You do not need strong immune-suppressing medicines like systemic steroids right before starting.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ABL103 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and effective.
This Phase 1 trial tests BAL0891, a new study treatment, in people with advanced solid tumors that have run out of treatment options, or in relapsed/refractory acute myeloid leukemia (AML). The goal is to find a safe dose and see how well it may work in these hard-to-treat cancers.
This Phase 1/2 study tests an experimental medicine (RNK05047) in people with advanced solid tumors or diffuse large B‑cell lymphoma whose standard treatments haven’t worked or can’t be tolerated. It may help shrink tumors and improve control of the disease, but early-phase trials also focus on safety and dosing.
This early study tests a new medicine (BPI-460372) in adults with advanced solid cancers that have come back or can’t be treated with standard options. It may help by targeting specific cancer changes in certain tumors, and doctors will also learn the safest dose.
This Phase 1 study tests how safe a new drug (ABSK-021) is, what side effects it causes, and how the body processes it in people with advanced solid tumors. You may be eligible if your cancer has grown despite standard treatments or if no standard treatment exists.
This Phase 1 study tests how safe INCA33890 is in adults with advanced or metastatic solid cancers. Because it’s an early safety study, the main goal is to see how the body handles the drug and whether it causes side effects.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.